From: Association of retroperitoneal fibrosis with malignancy and its outcomes
Baseline characteristics | n = 111 | |
---|---|---|
Age at diagnosis of RPF (years) | 59.2 ± 15.0 | |
Mean follow-up duration (years) after RPF diagnosis | 9.3 ± 3.6 | |
Male, n (%) | 77 (69.4) | |
Retroperitoneal distributions, n (%) | ||
Periaortitisa | 94 (84.7) | |
Retroperitoneal tumor-like mass | 17 (15.3) | |
Systemic organ involvement, n (%) | ||
Lymph nodes | 18 (16.2) | |
Kidney | 13 (11.7) | |
Pancreas | 9 (8.1) | |
Salivary gland | 5 (4.5) | |
Lacrimal gland | 1 (0.9) | |
Hydronephrosis, n (%) | 66 (59.5) | |
Creatinine (mg/dL) (n = 100) | 2.0 ± 3.1 | |
ESR (mm/h) (n = 81) | 47.6 ± 31.6 | |
CRP (mg/dL) (n = 90) | 2.8 ± 4.4 | |
IgG (mg/dL) (n = 46) | 1522.3 ± 564.2 | |
IgG4 (mg/dL) (n = 51) | 302.7 ± 625.4 | |
IgG4 > 135 (mg/dL), n (%) | 23/51 (45.1) |